Firms: King & Wood Mallesons (Garvan); Minter Ellison (The Medical Research Commercialisation Fund (MRCF)).
Deal: The launch of Solvanix Pty Ltd.
Value: $2 million
Area: IP and technology
Key players: The KWM team was led by partner Scott Bouvier (pictured), supported by senior associate Ryan Thorne. KWM worked closely together with the Garvan commercialisation team of Christina Hardy, Katrina Frankcombe and Peter Whitfeld to execute the transaction.
KWM advised on all aspects of the deal, including negotiating and preparing the licence agreement, shareholders agreement and other transaction documents.
Minter Ellison’s James Hutton was the lead partner acting for MRCF and was assisted by senior associate Nicole Reid.
Deal significance: Solvanix was set up to commercialise a novel technology that will improve the stability of therapeutic monoclonal antibodies. Developed by Garvan scientists, the new technology answers a significant need within the pharmaceutical industry – how to create fully human antibodies that are also stable and resistant to ‘aggregation’ or ‘stickiness’.